<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008120</url>
  </required_header>
  <id_info>
    <org_study_id>HMRF18190221</org_study_id>
    <nct_id>NCT05008120</nct_id>
  </id_info>
  <brief_title>Gut Microbiota in Major Depressive Disorders With and Without Rapid Eye Movement Behavior Disorder</brief_title>
  <official_title>Gut Microbiota in Major Depressive Disorders With and Without Rapid Eye Movement Behavior Disorder: Tracing a Subtype of Depression With Underlying Neurodegeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health and Medical Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the variations in gut microbiota compositions&#xD;
      between two subtypes of major depressive disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To identify the variations in gut microbiota compositions between two subtypes of&#xD;
      major depressive disorder (MDD), namely those with and without REM sleep behavior disorder&#xD;
      (RBD). To correlate the microbiota composition with depressive severity and prodromal markers&#xD;
      of α-synucleinopathy.&#xD;
&#xD;
      Design: Case-control study Setting: Established clinical cohorts consisting of patients with&#xD;
      comorbid MDD+RBD and MDD only and a group of sexand age-matched healthy control Participants:&#xD;
      Patients with comorbid MDD+RBD (n=55), patients with MDD only (n=55), and healthy control&#xD;
      (n=55).&#xD;
&#xD;
      Main outcome measures: The abundance and composition of gut microbiota, severity of&#xD;
      depressive symptoms, and prodromal markers of α-synucleinopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composition of gut microbiota</measure>
    <time_frame>Day 0</time_frame>
    <description>Colonic fecal bacterial composition across two heterogeneous groups of MDD (with and without RBD) and a group of the sex- and age-matched healthy controls</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>MDD + RBD</arm_group_label>
    <description>Clinical diagnosis of lifetime major depressive disorder, based on the M.I.N.I.;&#xD;
RBD diagnosis according to the International classification of sleep disorder (ICSD) 3rd edition, fulfilling both the clinical and video-polysomnography (vPSG) criteria;&#xD;
Depressive symptoms onset before RBD onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>Age-and sex-matched with MDD+RBD probands;&#xD;
Lifetime diagnosis of MDD based on M.I.N.I.;&#xD;
Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)&#xD;
Free of RBD symptoms or other hallmark features of RBD (e.g. REM Sleep Without Atonia, RWSA) by vPSG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health control</arm_group_label>
    <description>Age-and sex-matched with MDD+RBD subjects;&#xD;
Free of psychiatric disorders based on M.I.N.I.;&#xD;
Without a personal history or a family history of RBD or neurodegenerative diseases (i.e. dementia and PD)&#xD;
Free of RBD symptoms or RWSA by vPSG</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Health control</arm_group_label>
    <arm_group_label>MDD</arm_group_label>
    <arm_group_label>MDD + RBD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will perform 16S ribosomal RNA (rRNA) gene sequencing on the fecal microbiome of all&#xD;
      individuals. About 20g of the stool sample will be collected from each subject in a sterile&#xD;
      container and transferred to the laboratory as soon as possible after collection. All samples&#xD;
      arriving in the laboratory will be placed at -80°C before DNA extraction.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects of the current study would be recruited from our established cohort of&#xD;
        patients with MDD (with and without RBD). Three groups of subjects are included in the&#xD;
        current study, namely healthy control, patients with MDD only, and patients with MDD+RBD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age-and sex-matched with MDD+RBD subjects;&#xD;
&#xD;
          2. Free of psychiatric disorders based on M.I.N.I.;&#xD;
&#xD;
          3. Without a personal history or a family history of RBD or neurodegenerative diseases&#xD;
             (i.e. dementia and PD)&#xD;
&#xD;
          4. Free of RBD symptoms or RWSA by vPSG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of narcolepsy and other neurodegenerative diseases that may give rise to RBD&#xD;
             and RWSA;&#xD;
&#xD;
          2. Severe psychiatric illness that could not permit a valid written informed consent or&#xD;
             otherwise is not suitable for participating in a study;&#xD;
&#xD;
          3. Use of antibiotics within one month and the use of probiotics within three days prior&#xD;
             to sample collection;&#xD;
&#xD;
          4. Pre-existing or post-operation of gastrointestinal diseases (e.g. inflammatory bowel&#xD;
             disease, gastrointestinal cancer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mandy Yu, MPH</last_name>
    <phone>852-39197593</phone>
    <email>mandyyu@cuhk.edu.hk</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Wing Yun Kwok</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Major depressive</keyword>
  <keyword>Neurodegeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be handled and stored under Department of Psychiatry and PI will be responsible for the safekeeping.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

